Logo

UCFIW

CN Healthy Food Tech Group Corp.

UCFIW

CN Healthy Food Tech Group Corp. • NASDAQ
$0.09 ▼ -35.71% (-0.05)
Market Cap $4.70 M
52w High $0.16
52w Low $0.09
Dividend Yield 0%
P/E 0
Volume 147.95K
Outstanding Shares 52.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $6.093M $1.207M $2.072M 34.004% $0 $2.953M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $41.433M ▲ $50.753M ▲ $39.942M ▲ $10.811M ▲
Q3-2024 $19.506M $33.767M $24.648M $9.119M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $2.072M $20.264M $2.755M $0 $21.927M $20.237M

Five-Year Company Overview

Income Statement

Income Statement The income statement is still at a very early, almost experimental stage. Reported revenue is tiny and roughly matched by costs, which means the company is essentially hovering around break‑even with no meaningful profit yet. With only a single year of very small-scale data, it is hard to see clear trends in growth, margins, or efficiency. Overall, the business looks more like a young platform being set up than a mature operating company with a proven earnings engine.

Balance Sheet

Balance Sheet The balance sheet is very small and simple. Assets are limited and mostly held as cash, with no reported financial debt. Equity is modest, reflecting a company that has not yet built up a large base of operations, property, or retained profits. The absence of debt reduces financial strain, but the very small size of the asset base also means there is limited cushion if the company faces setbacks or needs to invest heavily to grow.

Cash Flow

Cash Flow Cash flow currently looks positive and almost entirely driven by basic operations, with virtually no spending on long‑term assets. This can reflect a lightweight, asset‑light model at the outset, but it can also mean the company has not yet started investing meaningfully in scaling production, marketing, or technology. Given the early stage and the unusual simplicity of the cash flows, today’s pattern should be treated as temporary rather than a reliable guide to how cash will behave once the business actually ramps up.

Competitive Edge

Competitive Edge The company is positioning itself as a health food and food‑biotech player in Asia, targeting a wellness market that is growing but very crowded. It offers a broad mix of grain‑based foods and supplements, which may help reach different customer segments but does not yet clearly set it apart from other wellness brands. Brand strength, distribution reach, and proof of health benefits are not yet well established in public information. On top of that, the recent trading halt of its stock and warrants due to regulatory review introduces additional uncertainty and may weigh on its visibility and credibility until resolved.

Innovation and R&D

Innovation and R&D The company describes itself as active in food biotechnology and healthy products, but publicly available details on specific technologies, proprietary formulas, or protected intellectual property are limited. There is no clear evidence yet of a strong technological edge, patented platform, or unique scientific approach that would protect margins over time. Any future moat is more likely to come from brand trust, differentiated product formulations, and strong online/offline distribution rather than from deep, defensible science—at least based on what is currently disclosed. More concrete R&D disclosures will be important to judge whether it can rise above being just another health food label.

Summary

Overall, CN Healthy Food Tech Group Corp. looks like a newly listed, very early-stage company with tiny current operations, a clean but minimal balance sheet, and undeveloped earnings power. Its strategy targets an attractive but highly competitive Asian health and wellness market, yet its specific edge—whether through innovation, branding, or distribution—remains unclear in public materials. The corporate history via SPAC merger adds structural complexity, and the ongoing trading halt tied to regulatory review is a key overhang. Any assessment of its long‑term potential will depend on how it resolves the regulatory issues, proves it can grow real sales, and demonstrates clearer, defensible differentiation in products and technology.